Market Cap | 5.96M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -5.09M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -40.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -50.00% |
Dividend | N/A | Price/Book | 9.26 | EPS next 5Y | - | 52W High Chg | -88.00% |
Recommedations | - | Quick Ratio | 13.39 | Shares Outstanding | 2.25M | 52W Low Chg | 1.00% |
Insider Own | 23.47% | ROA | -64.47% | Shares Float | 1.98M | Beta | -0.32 |
Inst Own | 5.08% | ROE | -111.07% | Shares Shorted/Prior | 19.57K/14.46K | Price | 3.23 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 126,453 | Target Price | - |
Oper. Margin | - | Earnings Date | May 8 | Volume | 61,155 | Change | -6.10% |
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Bernards Rene | Director Director | Oct 02 | Buy | 2.4 | 10,000 | 24,000 | 25,000 | 10/05/23 |
van der Baan Bastiaan Jeroen | President and CEO President and CEO | Oct 03 | Buy | 2.80 | 10,000 | 28,000 | 11,000 | 10/05/23 |
Bernards Rene | Director Director | Dec 15 | Buy | 0.51 | 15,000 | 7,650 | 150,000 | 12/16/22 |
FORMAN ERIC | Vice President and C.. Vice President and COO | Nov 17 | Buy | 0.56 | 21,059 | 11,793 | 98,142 | 11/21/22 |
Bernards Rene | Director Director | Nov 14 | Buy | 0.53 | 52,500 | 27,825 | 125,000 | 11/15/22 |